A Phase 2 Study of XL147 in Subjects with Advanced or Recurrent Endometrial Carcinoma The primary objectives of this study are: • To estimate the efficacy endpoints of: 1) ORR (confirmed complete response [CR] or confirmed PR), and 2) rate of 6-month PFS (PFS6) of XL147 in relation to ...

• Country None
• organs None
• Specialty None

A Study to Determine the Safety and Efficacy of Cabozantinib (XL184) in Patients with Metastatic Castration-resistant Prostate Cancer who have Received Prior Docetaxel and Prior Abiraterone or MDV3100 The objective of this study is to evaluate the effect of cabozantinib compared to prednisone on overall survival in men with previously treated metastatic castration-resistant prostate cancer with bon...

• Country None
• organs None
• Specialty None

An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 versus Placebo in Subjects with Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer To evaluate progression free survival (PFS) with XL184 treatment as compared with placebo in subjects with unresectable, locally advanced or metastatic medullary thyroid carcinoma (MTC).

• Country None
• organs None
• Specialty None

A study of cabozantinib vs. placebo in subjects with a form of liver cancer who have previously received sorafenib The objective of this study is to evaluate the effect of cabozantinib compared with placebo on overall survival in subjects with advanced HCC previously treated with sorafenib.

• Country None
• organs None
• Specialty None

A Phase 1/2 Study of XL147 Administered in Combination with Trastuzumab or Paclitaxel and Trastuzumab in Subjects with Metastatic Breast Cancer who have Progressed on a Previous Trastuzumab- Based Regimen The primary objectives are: • To evaluate the safety and tolerability of XL147 in combination with trastuzumab and in combination with trastuzumab and paclitaxel. • To determine the maximum tolerated ...

• Country None
• organs None
• Specialty None